What type of treatment is militizumab?

Milikizumab (Mirikizumab) is a humanized IgG4 monoclonal antibody, a biological agent targeting the cytokine pathway, specifically designed to block the p19 subunit of the inflammatory factor interleukin-23 (IL-23). IL-23 is a key factor in regulating T cell differentiation and activation in the immune system, especially playing a central role in the development of Th17 cells. A variety of inflammatory cytokines secreted by Th17 cells, such as IL-17 and IL-22, are closely related to the occurrence and development of chronic inflammatory diseases. Therefore, by blocking IL-23, militizumab can effectively slow down or reverse the inflammatory process and is a typical targeted immunomodulatory drug.

Different from traditional non-specific immunosuppressants, the biggest advantages of milizumab are its high targeting and lower risk of side effects of systemic immunosuppression. It does not act on a wide range of immune pathways, but precisely blocks IL-23, a key inflammatory factor, which can control the disease while reducing interference with normal immune function. This selective mechanism allows militizumab to exhibit good safety in clinical applications, especially for patients who are intolerant or ineffective of conventional treatments.

From a molecular structure perspective, Milizumab usesIgG4 isotype. This antibody structure is characterized by weak immune effector function and is more suitable for blocking cytokines rather than mediating cytotoxicity. In addition, IgG4 antibodies have low immunogenicity, which reduces the probability of patients producing drug-resistant antibodies (ADA), which is particularly important in long-term treatment of chronic diseases and helps improve the persistence of efficacy and treatment compliance.

The development of Militizumab is based on in-depth research on theIL-23 signaling pathway. Currently, targeted antibody drugs targeting the IL-23p19 subunit have received great attention in the treatment of immune diseases and are a hot topic in the treatment of new-generation inflammatory diseases.

Reference materials:https://omvoh.lilly.com/